IO Biotech stockholders elect three directors and ratify EY as auditor at 2024 annual meeting

IO Biotech, Inc.

Kathleen Sereda Glaub, Peter Hirth, and Mai-Britt Zocca elected as Class III directors until 2027.
Votes for each director exceeded 42 million; broker non-votes 3.9 million on each.
Ratification of EY as independent auditor for FY 2024 approved with 47.2 million for, 67k against.
No other matters were voted on at the June 6, 2024 annual meeting.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.